Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Stocks To Watch: ARWR, AUPH, IMGN, IMMU, RAD, REPH

Published 12/27/2019, 10:35 AM
Updated 07/09/2023, 06:31 AM

  • Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is in a beautiful, month-long, coil that I think is about to explode. On Thursday, it popped 2.43, or 3.76%, and closed at 66.99, after reaching a high of 67.98, on 1.4 million shares. If it breaks down, my stop is under 60. If it continues higher, the next move is 73, and then we’re looking at 90 as the next target going forward

  • Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has rock-n-rolled since it exploded out of a breakaway gap in early Dec. It had a one-day pullback, reversed, and has been up nearly every day, gaining another 91 cents, or 4.44%, to 21.42, reaching a high of 21.89, on 2.8 million shares on Thursday. It’s near my target of 22. My next target is 25.

  • ImmunoGen , Inc. (NASDAQ:IMGN), after pausing for a couple days, extended its move on Thursday by 34 cents, or 6.23%, to 5.80, reaching a high of 5.97, on 4.3 million shares. It looks to me like it’s headed to 7-7 1/4 next.

  • Immunomedics , Inc. (NASDAQ:IMMU) also broke out of a wedge on Thursday and popped 1.17, or 5.7%, to 21.67, after reaching a high of 22.22, on 5.4 million shares. That’s the best volume for this stock in several weeks. It looks like it’s headed to 24, and then 27.

  • Rite Aid Corporation (NYSE:RAD) broke out the first of Nov, pulled back for over six weeks before it exploded, and has in six sessions gone from 7.70 to nearly 19 1/4 on Thursday, after popping 3.05, or 19%, to 19.19, with a high of 19.22, on 26.4 million shares traded. This stock made 150% move in a week and a half on big volume. Is it overbought? Yes. Is it at resistance? Yes. I expect a little follow-through, but be careful on Friday.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

  • Recro Pharma, Inc. (NASDAQ:REPH) broke out of a wedge a week ago, then sat in there and coiled for three day, and then on Thursday, it popped 36 cents, or 2%, to 18.36, with a high of 18.64, on 257,753 shares traded. It looks like it wants to go higher. This swing is now targeting 24.

Stocks on the long side included Acorda Therapeutics, Inc. (ACOR), Acasti Pharma Inc. (ACST), Aldeyra Therapeutics, Inc. (ALDX), Aravive, Inc. (ARAV), Arrowhead Pharmaceuticals, Inc. (ARWR), Aurinia Pharmaceuticals Inc. (AUPH), BioDelivery Sciences International, Inc. (BDSI), Constellation Pharmaceuticals, Inc. (CNST), ImmunoGen, Inc. (IMGN), Immunomedics, Inc. (IMMU), Direxion Daily Jr Gld Mnrs Bull 3X ETF (JNUG), Maxar Technologies Inc. (MAXR), Nordic American Tankers Limited (NAT), NewLink Genetics Corporation (NLNK), Novan, Inc. (NOVN), Oncolytics Biotech Inc. (ONCY), Prothena Corporation plc (PRTA), Rite Aid Corporation (RAD), Recro Pharma, Inc. (REPH), Stage Stores, Inc. (SSI), and Tetraphase Pharmaceuticals, Inc. (TTPH).

Watch video here...

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.